Adrenal chromaffin cells (ACCs) are specialized neuroendocrine cells located in the adrenal medulla that serve as a critical model system for understanding catecholamine biosynthesis, regulated secretion, and their roles in neurodegenerative diseases. These cells share a common developmental origin with sympathetic neurons, arising from the neural crest, and represent an intermediate phenotype between neurons and endocrine cells[1][2].
Chromaffin cells are named for their characteristic cytoplasmic granules that oxidize and turn brown when exposed to chromium salts—a histological property first described in the late 19th century. These cells are the primary source of catecholamines (epinephrine, norepinephrine, and dopamine) in the body and play essential roles in the stress response through their secretion of these neurotransmitters into the bloodstream[3].
The relevance of adrenal chromaffin cells to neurodegenerative disease research spans multiple dimensions. First, they serve as a accessible model for studying catecholamine metabolism, which is profoundly altered in Parkinson's disease. Second, they have been used as donor cells in transplantation therapies for Parkinson's disease. Third, the biochemical machinery they employ for catecholamine synthesis, storage, and release provides insights into mechanisms that go awry in neurodegeneration[4][5].
Adrenal chromaffin cells derive from multipotent neural crest cells that migrate to the nascent adrenal medulla during embryonic development. These neural crest cells give rise to both sympathetic neurons and chromaffin cells, with the decision between these fates influenced by local environmental cues, particularly glucocorticoids from the developing adrenal cortex[1:1][2:1].
The differentiation process involves:
Chromaffin cells and sympathetic neurons share many molecular features but differ in key aspects:
| Feature | Chromaffin Cells | Sympathetic Neurons |
|---|---|---|
| Structure | Epithelial-like, clustered | Axonal projections |
| Secretion | Endocrine (blood-borne) | Synaptic (neuronal) |
| Location | Adrenal medulla | Paravertebral ganglia |
| Activity | Continuous baseline secretion | Phasic, activity-dependent |
This developmental relationship explains why chromaffin cells express many neuronal proteins, including synaptic vesicle-associated proteins, ion channels, and neuropeptide precursors, making them excellent models for neuronal function[6].
Chromaffin cells are the primary site of epinephrine synthesis in the body. The catecholamine biosynthetic pathway involves a series of enzymatic reactions[7][8]:
Key enzymes in this pathway include:
Chromaffin cells contain dense-core secretory granules (100-300 nm diameter) that store catecholamines and neuropeptides. Each granule contains approximately 10,000-20,000 molecules of catecholamines complexed with ATP and chromogranin/secretogranin proteins[9][10][11].
The exocytosis mechanism involves:
The actin cytoskeleton plays a critical role in granule trafficking and positioning, with detailed regulation by various protein kinases and phosphatases[10:1].
Chromogranin A (CgA) is the major soluble protein in chromaffin granules and serves multiple functions[12][13][14]:
CgA-derived peptides have demonstrated neuroprotective properties in experimental models, suggesting potential therapeutic applications[14:1].
Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to depletion of dopamine in the striatum. However, the catecholamine system is more broadly affected in PD, with alterations extending beyond the central nervous system[7:1][15]:
Recent research has identified alpha-synuclein pathology in peripheral catecholamine neurons, including those innervating the adrenal medulla[16]. This finding has several implications:
Post-mortem studies have revealed:
These alterations suggest that the adrenal catecholamine system may provide compensatory mechanisms in PD, and modulating this system could offer therapeutic benefits.
Adrenal chromaffin cells have been investigated as a cell therapy for Parkinson's disease since the 1980s. The rationale included[17][18][19][4:1][20]:
Clinical trials conducted between 1985 and 2005 showed variable results:
Limitations identified:
Recent research has focused on enhancing chromaffin cell-based therapies[4:2][5:1][21][22]:
The adrenal medulla produces several neurotrophic factors that support chromaffin cell survival and have potential neuroprotective effects[21:1][23][22:1]:
These factors have been investigated for their potential to protect degenerating dopaminergic neurons in PD models.
Adrenal chromaffin cells undergo age-related changes that may contribute to their dysfunction in neurodegeneration[24]:
These changes mirror those observed in neurodegenerative diseases, suggesting chromaffin cells may serve as a model for studying aging-related neuronal dysfunction[25].
The relationship between catecholamine metabolism and protein aggregation is complex[26][25:1]:
This bidirectional relationship between catecholamine dysregulation and protein aggregation provides insight into the pathogenesis of both Parkinson's and Alzheimer's diseases.
Adrenal chromaffin cells provide excellent research models:
These models enable detailed studies of:
Modern approaches using chromaffin cells include:
Schultzberg M, Dreyfus CF, Gershon MD, et al. Neuronal development in the adrenal medulla. J Comp Neurol. 1979. ↩︎ ↩︎
Bohn MC, Goldstein M, Black IB. Role of glucocorticoids in the development of adrenal medulla. Dev Biol. 1983. ↩︎ ↩︎
Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev. 2009. ↩︎
Huang J, Yang H, Liu C. Chromaffin cell-based therapy for Parkinsons disease: progress and challenges. Prog Neurobiol. 2020. ↩︎ ↩︎ ↩︎
Unfrey J, Sarva H, Deik A. Adrenal medulla transplantation for Parkinsons disease. Mov Disord. 2021. ↩︎ ↩︎
Livett BG. Adrenal chromaffin cells: a model for regulated peptide secretion. Mol Cell Neurosci. 1993. ↩︎
Nagatsu T. Changes of catecholamines in neurodegeneration. J Neural Transm Suppl. 2010. ↩︎ ↩︎
Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors in neurodegenerative disease. Nat Rev Neurosci. 2006. ↩︎
Aunis D. Exocytosis in chromaffin cells: from protein secretion to synaptic transmission. J Physiol (Paris). 1998. ↩︎
Bader MF, Gasman B, Chasserot-Golaz S. The role of the actin cytoskeleton in neuroendocrine secretion. Ann N Y Acad Sci. 2002. ↩︎ ↩︎
O'Connor DT, Mahata SK, Taupenot L, et al. Chromogranin A in autonomic and neuroendocrine signaling. Adv Pharmacol. 2018. ↩︎
Guillemain I, Taupenot L, Aunis D. Chromogranin A and the secretogranin family. Ann Endocrinol (Paris). 2000. ↩︎
Boras E, Carceller F, Boix J. Chromogranin A in the adrenal medulla and in neurodegenerative disease. Microsc Res Tech. 2003. ↩︎
Zhang L, Wang Y, Liu Q. Chromogranin A and its fragments in neuroprotection. Front Cell Neurosci. 2018. ↩︎ ↩︎
Partoens P, S追dp W, De B, et al. Catecholamine biosynthesis and neurodegeneration. J Neural Transm Suppl. 1999. ↩︎
Thompson J, Marsh J, Blenkinsop P. alpha-Synuclein in peripheral catecholaminergic neurons. Acta Neuropathol Commun. 2018. ↩︎
Polak M, Shibahara Y, Vrancken J, et al. Chromaffin cells as transplantation in neurodegeneration. J Exp Med. 1985. ↩︎
Freed WJ, Morihisa JM, Spoor E, et al. Transplanted adrenal chromaffin cells in rat brain. Nature. 1978. ↩︎
Fine A. Cell transplantation for Parkinsons disease. Brain Res. 1985. ↩︎
Ortiz L, Aulisi R, Young R, et al. Adrenal medullary transplants in Parkinsons disease clinical outcomes. Exp Neurol. 2003. ↩︎
Rona S, Korczyn A, Gurevich T, et al. Neurotrophic factors in adrenal medulla and their role in neurodegeneration. J Neural Transm. 2015. ↩︎ ↩︎
Morata P, Vargas A, Garca M, et al. BDNF expression in adrenal medulla and its therapeutic potential. Mol Neurobiol. 2020. ↩︎ ↩︎
Rosenstein J, Kwon Y, Kim H. VEGF and BDNF in chromaffin cell survival and neuroprotection. Cell Mol Neurobiol. 2020. ↩︎
Martinez A, Perez-Castillo A, Santos M. Oxidative stress in adrenal chromaffin cells during aging. Free Radic Biol Med. 2019. ↩︎
Singh V, Chand S, Singh I. Autophagy and catecholamine toxicity. Cell Death Discov. 2017. ↩︎ ↩︎
Hernandez F, Avila J, Lucas J. Catecholamine metabolism and protein aggregation. J Alzheimers Dis. 2016. ↩︎